View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
December 4, 2018

NeuroPace reports positive long-term results of Next-Gen RNS system

NeuroPace has reported positive results from a long-term study of its Next-Gen RNS System to treat refractory epilepsy in the US. 

NeuroPace has reported positive results from a long-term study of its Next-Gen RNS System to treat refractory epilepsy in the US.

The nine-year study was conducted at 33 epilepsy centres with a total of 256 patients who have not experienced an adequate response to medication.

Results showed a significant reduction in seizures and improved quality of life for patients implanted with the neuromodulation system, the company said.

Next-Gen RNS System is a closed loop brain-responsive neurostimulation device launched by the company in June. Based on a brain-computer interface, the system continuously monitors brain waves and sends imperceptible electrical pulses, even before the occurrence of seizures.

Study principal investigator Dr Dileep Nair said: “This nine-year landmark study is the largest and longest prospective neuromodulation trial in the field of epilepsy.

“These insights have the potential to lead to the treatment of other brain disorders that affect millions of people worldwide.”

“Brain-responsive neurostimulation not only demonstrates compelling long-term seizure reduction for patients, but also provides physicians with ongoing neural recordings that have improved our understanding and treatment of seizures.”

During the study, nearly three out of four patients experienced at least 50% seizure reduction, while one in three achieved a decrease of at least 90%. Across all patients, median seizure reduction was 75% at nine years.

Investigators also observed six months or longer seizure-free periods in 28% of participants, while 18% had seizure-free periods of one year or longer.

In addition, improvements to quality of life in patients were sustained over nine years, without any side-effects associated with chronic stimulation.

NeuroPace chief medical officer Martha Morrell said that completion of the study is set to be followed by application of artificial intelligence to the obtained data set. The technology is expected to optimise therapy settings and improve clinical outcomes.

Morrell added: “The neural data has revealed remarkable discoveries about how the brain functions over months and years; these insights have the potential to lead to the treatment of other brain disorders that affect millions of people worldwide.”

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU